Dr. David E. Martin | Testimony - Corona Virus Patents and information

Dr. David E. Martin | Testimony - Corona Virus Patents and information

released originally 14 Jul, 2021

Evidence given to the German-led international Corona Investigative Committee on Friday July 9 by Dr David Martin, who runs a US company monitoring innovations relevant to financial interests. He said a review of more than 4,000 patents issued around the SARS (Severe Acute Respiratory Syndrome) coronavirus had led to the dramatic conclusion: ‘We made SARS’. Today we continue an account of his evidence, of which the live-streamed video is here.

THE United States has a federal law known as the RICO Act. It sounds friendly, but is aimed at something deadly: Racketeer Influenced and Corrupt Organisations. It was introduced due to the complexity of bringing successful charges against organised crime gangs.

Dr David Martin told the Corona Investigative Committee that in April 2003, a US drug company applied for a patent on anti-viral agents, treatment, and control of infections by coronavirus, just three days after the Centres for Disease Control sought to patent the SARS coronavirus itself – in a supposedly secret application. The first SARS outbreak had occurred in February that year in China.

His description led the inquiry committee chairman, German lawyer Reiner Fuellmich, who specialises in exposing corporate swindles, to comment: ‘This could well blow up into a RICO case ultimately.’

Martin replied: ‘Not could blow up – it is a RICO case. And the RICO pattern which was established in April 2003 for the first coronavirus was played out to exactly the same schedule when we see SARS-COV-2 show up.’

He claimed that Moderna (originally ModeRNA) were given the genetic sequence for the spike protein that forms the basis of their Covid vaccine by phone from the vaccine research centre at the National Institute of Allergy and Infectious Diseases even before the novel subclade of the virus had been defined. ‘How do you treat a thing before you actually have the thing?’ he asked.

Moderna (originally ModeRNA Therapeutics) is a Massachusetts-based company founded in 2010 by a team of investors to develop RNA (ribonucleic acid) technology, thought to hold huge promise in harnessing the power of RNA code to make new medicines inside our bodies.

Another important date, Martin said, is June 5, 2008. This was around the time when the Defence Advanced Research Programme (DARPA) in the US took an interest in coronavirus as a biological weapon. It was also the date when a drug company, now part of the Paris-based pharma giant Sanofi, filed a series of patents targeting genes that 12 years later are said to be the novel features of SARS-COV-2 that make it a health hazard for humans.

From 2008 onwards, patent filings from numerous organisations identified ‘every attribute’ of the virus, as it eventually came to be described. The reference paper routinely used to identify it, published in March 2020, claimed to show that the novel features had come about in nature, and that the virus ‘originated from multiple naturally-occurring recombinant events among those viruses present in bats and other wildlife species’.

Martin said: ‘Unfortunately, if you actually take what they report to be novel, you find 73 patents, issued between 2008 and 2019, which have the elements which are allegedly novel in SARS-COV-2. So – there was no outbreak of SARS, because we had engineered all of the elements of that.’

The supposedly new virus had been said since 2016 to be poised for human emergence. But ‘it was not only poised for human emergence, it was patented for commercial exploitation – 73 times,’ Martin said. ‘Any assertion that this pathogen is somehow unique or novel falls apart on the actual gene sequences, which are published in the patent record.’

Researchers at the University of North Carolina at Chapel Hill (who collaborated with the laboratory in Wuhan, China, in the coronavirus ‘gain of function’ work) along with the National Institute of Allergy and Infectious Diseases and Moderna, began the sequencing of a spike protein vaccine in November 2019, a month before the Wuhan outbreak happened.

Martin also challenged the idea that injecting people with the RNA sequence for the spike protein is a true vaccine. The theory behind it is that by teaching the immune system to recognise the protein, which in itself has toxic effects, the body will be better equipped to deal with the toxin when exposed to the virus. . .

Original Source
https://www.datascienceassn.org/content/dr-david-e-martin-testimony-july-9th-2021